Understudied Hyperphosphatemia (Chronic Kidney Disease) Treatment Targets and New Biological Approaches

Medicina (Kaunas). 2023 May 16;59(5):959. doi: 10.3390/medicina59050959.


Hyperphosphatemia is a secondary disorder of chronic kidney disease that causes vascular calcifications and bone-mineral disorders. As per the US Centers for Disease Control and Prevention, renal damage requires first-priority medical attention for patients with COVID-19; according to a Johns Hopkins Medicine report, SARS-CoV-2 can cause renal damage. Therefore, addressing the research inputs required to manage hyperphosphatemia is currently in great demand. This review highlights research inputs, such as defects in the diagnosis of hyperphosphatemia, flaws in understanding the mechanisms associated with understudied tertiary toxicities, less cited adverse effects of phosphate binders that question their use in the market, socioeconomic challenges of renal treatment and public awareness regarding the management of a phosphate-controlled diet, novel biological approaches (synbiotics) to prevent hyperphosphatemia as safer strategies with potential additional health benefits, and future functional food formulations to enhance the quality of life. We have not only introduced our contributions to emphasise the hidden aspects and research gaps in comprehending hyperphosphatemia but also suggested new research areas to strengthen approaches to prevent hyperphosphatemia in the near future.

Keywords: chronic kidney disorder; hyperphosphatemia; phosphate accumulating organisms; phosphate-controlled diet.

Publication types

  • Review

MeSH terms

  • COVID-19* / complications
  • Humans
  • Hyperphosphatemia* / complications
  • Hyperphosphatemia* / therapy
  • Phosphates / therapeutic use
  • Quality of Life
  • Renal Dialysis / adverse effects
  • Renal Insufficiency, Chronic* / complications
  • Renal Insufficiency, Chronic* / therapy
  • SARS-CoV-2


  • Phosphates